Pan-cancer characterization of receptor tyrosine kinases alterations to sort targetable drivers from passengers

被引：0
|
作者：
Vanacker, H. [1 ]
Attignon, V. K. [2 ]
Brahmi, M. [1 ]
Dufresne, A. [1 ]
Cassier, P. [1 ]
Carbonnaux, M. [3 ]
Pissaloux, D. [2 ]
Boyault, S. [2 ]
Wang, Q. L. [2 ]
Tredan, O. [1 ]
Tirode, F. [2 ]
Blay, J-Y [1 ]
机构：
[1] Ctr Leon Berard, Med Oncol Dept, Lyon, France
[2] Ctr Leon Berard, Translat Res Dept, Lyon, France
[3] CH Annecy Gennevois, Oncol Dept, Epagny Metz Tessy, France
来源：
ANNALS OF ONCOLOGY | 2022年 / 33卷 / 08期
关键词：
D O I：
10.1016/j.annonc.2022.09.007
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S1385 / S1385
页数：1
相关论文
共 25 条
  • [21] Identification of genetic alterations in the human EGF receptor tyrosine kinase domain in tumor samples from non-small-cell lung cancer patients
    Meister, M
    Muley, T
    Schnabel, P
    Hoffmann, H
    Drings, P
    Dienemann, H
    Lahm, H
    LUNG CANCER, 2005, 49 : S110 - S110
  • [22] Characterization of genetic mutation spectra and identification of gene amplification and fusion variants in cell-free nucleic acid from cultured cancer cell media and liquid biopsy specimens using Oncomine™ Pan-Cancer Cell-Free Assay
    Cao, Ru
    Lea, Kris
    Jasti, Madhu
    Schageman, Jeff
    Hanif, Khalid
    Li, Yanchun
    Gu, Jian
    Bagai, Varun
    Kshatriya, Priyanka
    Wikman, Harriet
    Loges, Sonja
    Bramlett, Kelli
    CANCER RESEARCH, 2019, 79 (13)
  • [23] Dynamic contrast-enhanced magnetic resonance imaging as a biomarker for the pharmacological response of PTK787/ZK 222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases, in patients with advanced colorectal cancer and liver metastases:: Results from two phase I studies
    Morgan, B
    Thomas, AL
    Drevs, J
    Hennig, J
    Buchert, M
    Jivan, A
    Horsfield, MA
    Mross, K
    Ball, HA
    Lee, L
    Mietlowski, W
    Fuxius, S
    Unger, C
    O'Byrne, K
    Henry, A
    Cherryman, GR
    Laurent, D
    Dugan, M
    Marmé, D
    Steward, WP
    JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (21) : 3955 - 3964
  • [24] Molecular alterations and poziotinib efficacy, a pan-HER inhibitor, in human epidermal growth factor receptor 2 (HER2)-positive breast cancers: Combined exploratory biomarker analysis from a phase II clinical trial of poziotinib for refractory HER2-positive breast cancer patients
    Kim, Ji-Yeon
    Lee, Eunjin
    Park, Kyunghee
    Jung, Hae Hyun
    Park, Woong-Yang
    Lee, Kyung-Hun
    Sohn, Joohyuk
    Lee, Keun Seok
    Jung, Kyung Hae
    Kim, Jee Hyun
    Lee, Ki Hyeong
    Im, Seock-Ah
    Park, Yeon Hee
    INTERNATIONAL JOURNAL OF CANCER, 2019, 145 (06) : 1669 - 1678
  • [25] Molecular alterations and poziotinib, a pan-HER inhibitor efficacy in human epidermal growth factor receptor 2(HER2) positive breast cancers: Combined exploratory biomarker analysis from phase II clinical trial of poziotinib for refractory HER2 positive breast cancer(BC) patients
    Kim, Ji-Yeon
    Lee, Eunjin
    Park, Kyunghee
    Jung, Hae Hyun
    Park, Woong-Yang
    Lee, Kyung-Hun
    Sohn, Joo Hyuk
    Lee, Keun Seok
    Jung, Kyung Hae
    Kim, Jee-Hyun
    Lee, Ki Hyeong
    Im, Seock-Ah
    Park, Yeon Hee
    CANCER RESEARCH, 2018, 78 (04)
123